ArticleScience (New York, N.Y.)2022
Oncometabolite d-2HG alters T cell metabolism to impair CD8
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 3 pooled it
37.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
188 citing papers in PubMed, 3 syntheses or guidelines pooled it, 257 citations in OpenAlex.
- Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.Molecular oncology · 2024Pooled it
- Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets.Genes, chromosomes & cancer · 2024Pooled it
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia.Leukemia · 2026Article
- The diversity of terminal electron acceptors across eukaryotes.Trends in biochemical sciences · 2026Review
- The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy.Cells · 2026Review
- Targeting colorectal cancer and T‑cell metabolism for the treatment of colorectal cancer (Review).Oncology reports · 2026Review
- IL-21 controls CD8Zoological research · 2026Article
- Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma.International journal of molecular sciences · 2026Review
- Targeting the cancer metabolism-immunity interface: update and perspectives.Experimental hematology & oncology · 2026Review
- Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity.Experimental hematology & oncology · 2026Review
- Histone mark remodeling in cancer: an enhancer-centered perspective.Genes & genomics · 2026Review
- Solute carrier transporters as metabolic gatekeepers in tumor-microenvironment crosstalk.Acta pharmacologica Sinica · 2026Review
- IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.European urology · 2026Article
- Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements.Journal of advanced research · 2026Review
- An Integrated Immunometabolic Signature Predicts Prognosis and Immunotherapy Response in ccRCC and IdentifiesCancers · 2026Article
- mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy.Cell reports. Medicine · 2026Article
128 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
24 authors at 4 institutions in 2 countries.
Giulia NotarangeloDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3805-1834
Jessica B SpinelliDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3657-4578
Elizabeth M PerezBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-6198-8329
Gregory J BakerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5196-3961
Kiran KurmiDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1345-0196
Ilaria EliaDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0922-9429
Sylwia A StopkaDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3761-6899
Gerard BaquerDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4433-4972
Jia-Ren LinLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4702-7705
Alexandra J GolbyDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8461-9561
Shakchhi JoshiDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Heide F BaronChemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-1575-4529
Jefte M DrijversDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5675-5643
Peter GeorgievDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4613-1255
Alison E RingelDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6451-9376
Elma ZaganjorDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0600-7417
Samuel K McBrayerChildren's Medical Center Research Institute and Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9361-675X
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3364-1838
Arlene H SharpeBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-9736-2109
Kai W WucherpfennigBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-1829-302X
Sandro SantagataLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7528-9668
Nathalie Y R AgarDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3149-3146
Mario L SuvàBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-9898-5351
Marcia C HaigisDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2530-2681
Harvard University · USBrigham and Women's Hospital · USBroad Institute · USChildren's Medical Center · US
Funding
Understanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca, DAVID A REARDON · 2020 to 2026
$19.5MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2018 to 2022
$10.8MTRD 3 - Enabling Technologies for Intraprocedural GuidanceP41EB028741 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI Nobuhiko Hata, CLARE M TEMPANY · 2021 to 2026
$10.7MTrans Network ProjectU54CA210180 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SWANSON, KRISTIN R · 2016 to 2020
$10.2MMolecular mechanisms of Nutrient sensing in cancerR01CA213062 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2017 to 2021
$1.9MTraining in Image Guidance, Precision Diagnosis and TherapyT32EB025823 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI Fiona Fennessy, Lauren Jean O'Donnell · 2019 to 2026
$1.5MAdvancing technologies for the collection and analysis of high dimensional immunoprofiles and tumor imagesR50CA274277 · NCI · HARVARD MEDICAL SCHOOL · PI Jia-Ren Lin · 2022 to 2026
$879kNCI NIH HHS P01 CA236749NCI NIH HHS R01 CA213062NCI NIH HHS R50 CA274277NCI NIH HHS U54 CA210180NCI NIH HHS U54 CA225088NIBIB NIH HHS P41 EB028741NIBIB NIH HHS T32 EB025823
Abstract
Gain-of-function mutations in isocitrate dehydrogenase (IDH) in human cancers result in the production of d-2-hydroxyglutarate (d-2HG), an oncometabolite that promotes tumorigenesis through epigenetic alterations. The cancer cell-intrinsic effects of d-2HG are well understood, but its tumor cell-nonautonomous roles remain poorly explored. We compared the oncometabolite d-2HG with its enantiomer, l-2HG, and found that tumor-derived d-2HG was taken up by CD8
Indexed as
CarcinogenesisCD8-Positive T-LymphocytesGlutaratesIsocitrate DehydrogenaseNeoplasmsAnimalsGain of Function MutationHumansInterferon-gammaL-Lactate DehydrogenaseMicealpha-hydroxyglutarateGlutaratesIDH1 protein, humanInterferon-gammaIsocitrate DehydrogenaseL-Lactate Dehydrogenase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.